Selective JNK inhibitor. Competitively and reversibly inhibits JNK1, 2 and 3 (IC50
= 40 - 90 nM) with negligible activity at ERK2, p38β
and a range of enzymes. Active in vivo
. Exhibits reduced selectivity over other protein kinases under certain conditions. Protects renal tubular epithelial cells against ischemia/reperfusion-induced apoptosis. Prevents BMP9-induced osteogenic differentiation of MSCs. Essential component of medium for maintaining stem cells in naive pluripotent state. Available as part of the MAPK Inhibitor Tocriset™
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.
Bennett et al.
TAK1/JNK and p38 have opposite effects on rat hepatic stellate cells.
Schnabl et al.
SP600125, a selective JNK inhibitor, protects ischemic renal injury via suppressing the extrinsic pathways of apoptosis.
Wang et al.
Life Sci., 2007;80:2067
Activation of JNKs is essential for BMP9-induced osteogenic differentiation of mesenchymal stem cells.
Zhao et al.
BMB Rep., 2013;46:422
Derivation of novel human ground state naive pluripotent stem cells.
Gafni et al.
The citations listed below are publications that use Tocris products. Selected citations for SP 600125 include:
Showing Results 1 - 10 of 69